Rectal cancer
Conditions
Interventions
Tamsulosin Group:For patients scheduled to undergo TME surgery, tamsulosin 0.4 mg once daily is administered 4 hours before surgery until the second day after surgery. The catheter is removed on the s
Control Group:For patients scheduled to undergo TME surgery, give a placebo QD starting 4 hours before surgery until the second day after surgery. Remove the urinary catheter on the second day after s
Sponsors
The Sixth Affiliated hospital of Sun Yat-sen University
Eligibility
Sex/Gender
Male
Age
60 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Male patients aged >=60 years; 2. Colonoscopy pathological biopsy confirmed adenocarcinoma (including tubular adenocarcinoma, papillary adenocarcinoma, mucinous adenocarcinoma, signet ring cell carcinoma); 3. According to the 8th edition of the American Joint Committee on Cancer (AJCC) Cancer Staging Manual, preoperative evaluation shows clinical tumor stage T1-T3 N0 M0, requiring TME radical resection; 4. ASA score I-III; 5. Performance status on the ECOG (Eastern Cooperative Oncology Group) scale of 0 or 1; 6. The patient or family members can understand the study protocol and are willing to participate in this study, providing written informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients allergic to or contraindicated for tamsulosin; 2. Patients who have recently taken a-receptor agonists or a-receptor inhibitors, or who take related medications outside the study during the intervention phase; 3. Patients with pre-existing indwelling catheters, suprapubic catheters, or urinary stomas before intervention; 4. Patients with orthostatic hypotension (defined as a decrease in systolic blood pressure of 20 mmHg upon standing from a sitting position, or a decrease in diastolic blood pressure of 10 mmHg after 2-3 minutes of standing from a sitting position); 5. Patients who received preoperative neoadjuvant radiotherapy; 6. Patients with a preoperative IPSS score >=20; 7. Tumors invading the external sphincter and levator ani muscle or involving adjacent organs requiring combined organ resection; 8. Patients with intestinal obstruction, intestinal perforation, intestinal bleeding, or other conditions requiring emergency surgery; 9. Patients with uncontrolled preoperative infection or severe cardiovascular or endocrine system diseases, poorly controlled and unable to tolerate surgery; 10. Patients deemed by the investigator as unsuitable to participate in this clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Voluntary Urination Rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Postoperative Urinary Function;Postoperative Urinary Tract Infection Rate;Postoperative Recovery Outcomes;Perioperative Outcomes;Quality of Life; | — |
Countries
China
Contacts
Public ContactKang Liang
The Sixth Affiliated hospital of Sun Yat-sen University
Outcome results
None listed